Your browser doesn't support javascript.
loading
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Gutiérrez-Chamorro, Lucía; Felip, Eudald; Castellà, Eva; Quiroga, Vanessa; Ezeonwumelu, Ifeanyi Jude; Angelats, Laura; Esteve, Anna; Perez-Roca, Laia; Martínez-Cardús, Anna; Fernandez, Pedro Luis; Ferrando-Díez, Angelica; Pous, Anna; Bergamino, Milana; Cirauqui, Beatriz; Romeo, Marga; Teruel, Iris; Mesia, Ricard; Clotet, Bonaventura; Riveira-Muñoz, Eva; Margelí, Mireia; Ballana, Ester.
Afiliação
  • Gutiérrez-Chamorro L; AIDS Research Institute-IrsiCaixa and Health Research Institute Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Felip E; AIDS Research Institute-IrsiCaixa and Health Research Institute Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Castellà E; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Quiroga V; Department of Pathology, Hospital Germans Trias i Pujol, IGTP (Health Research Institute Germans Trias I Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Ezeonwumelu IJ; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Angelats L; AIDS Research Institute-IrsiCaixa and Health Research Institute Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Esteve A; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Perez-Roca L; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Martínez-Cardús A; Banc de Tumors, Health Research Institute Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Fernandez PL; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Ferrando-Díez A; Department of Pathology, Hospital Germans Trias i Pujol, IGTP (Health Research Institute Germans Trias I Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Pous A; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Bergamino M; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Cirauqui B; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Romeo M; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Teruel I; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Mesia R; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Clotet B; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Riveira-Muñoz E; AIDS Research Institute-IrsiCaixa and Health Research Institute Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Margelí M; AIDS Research Institute-IrsiCaixa and Health Research Institute Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916, Badalona, Spain.
  • Ballana E; Medical Oncology Department, Catalan Institut of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology) and IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona, 08916, Badalona, Spain. mmargeli@iconcologia.net.
Cell Oncol (Dordr) ; 47(1): 189-208, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37667113

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article